"...Paul Hopper's ability to pick up strong oncology assets on excellent valuations."
The Hopper oncology deal was announced on St Patricks Day.
VHL shares have been falling ever since - today sunk to $0.07. Why?
Because the market takes issue with your Hopper deal sentiment, maybe.
Directors have yet to explain why Hopper's oncology drug was discarded by previous licensee after Phase 1 trial.
Hopper publicly silent. Millen also.
As for Edison Research, I note the firm expects any TG-4010 royalties flowing via Transgene will be deferred two years 'til 2018.
Still, if BMS or Merck emerge as TG-4010 backers, VHL may rise from the floor.
"...Paul Hopper's ability to pick up strong oncology assets on...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
2.8¢ |
Change
0.002(7.69%) |
Mkt cap ! $48.11M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $44.61K | 1.648M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 579398 | 2.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.8¢ | 2318208 | 1 |
View Market Depth
| Last trade - 15.52pm 29/07/2025 (20 minute delay) ? |
| VHL (ASX) Chart |